Minimal residual disease in Philadelphia-positive acute lymphoblastic leukemia: Maximizing the clinical yield of testing

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
² Hematology, Department of Translational and Precision Medicine, "Sapienza" University, Rome, Italy.

Free article

Editorial

Antoine N Saliba et al. Am J Hematol. 2023 Aug.

Free article

. 2023 Aug;98(8):1168-1170.

doi: 10.1002/ajh.26993. Epub 2023 Jun 14.

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
² Hematology, Department of Translational and Precision Medicine, "Sapienza" University, Rome, Italy.

No abstract available

Comment on

Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Short NJ, et al. Am J Hematol. 2023 Aug;98(8):1196-1203. doi: 10.1002/ajh.26949. Epub 2023 May 15. Am J Hematol. 2023. PMID: 37183966

1. Della Starza I, De Novi LA, Santoro A, et al. Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(11):2838-2840.
1. Della Starza I, Nunes V, Lovisa F, et al. Droplet digital PCR improves IG−/TR-based MRD risk definition in childhood B-cell precursor acute lymphoblastic leukemia. Hema. 2021;5(3):e543.
1. Della Starza I, De Novi LA, Elia L, et al. Optimizing molecular minimal residual disease analysis in adult acute lymphoblastic leukemia. Cancers. 2023;15(2):374. doi:10.3390/cancers15020374.
1. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-3214.
1. Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111(9):4477-4489.